- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04936230
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To compare the overall response rates by 6 months in patients with advanced urothelial carcinoma when treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
SECONDARY OBJECTIVES:
I. To compare the response rates using immune related Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by central review.
II. To compare progression-free survival (PFS) and overall survival (OS) for patients treated with immunotherapy and immunotherapy plus radiotherapy.
III. To compare the rates of treatment discontinuation at 1 year. IV. To assess adverse events experienced by patients treated with immunotherapy and immunotherapy plus radiotherapy via the Common Terminology Criteria for Adverse Events (CTCAE) and Patient Reported Outcome (PRO)-CTCAE.
IV. To determine whether treatment effects are similar for key subgroups including those defined by the stratification variables.
QUALITY OF LIFE CORRELATIVE STUDY OBJECTIVES:
I. To compare patient-reported fatigue as assessed by the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue 8a from baseline through 24 months between patients treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
II. To compare health-related quality of life (HRQOL) as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core (C)30 from baseline through 24 months between patients treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
III. To compare urinary symptoms as assessed by the EORTC QLQ-BLM30 from baseline through 24 months between patients treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
IV. To compare patient-reported diarrhea, shortness of breath and pain as assessed by the EORTC QLQ-C30 from baseline through 24 months between patients treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
V. To compare health utilities and quality-adjusted survival between patients treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
VI. To compare other scale scores of the EORTC QLQ-C30 (global health status and quality of life; physical, role, emotional, cognitive, and social function; symptoms) and EORTC QLQ-BLM30 (urostomy problems, catheter problems, future perspectives, abdominal bloating and flatulence, body image, sexual function) at 45 days, and at 6, 12, and 24 months between patients treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive pembrolizumab intravenously (IV) over 25-40 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI), bone scan and/or positron emission tomography (PET) scan, as well as optional urine and blood sample collection throughout the study.
ARM B: Patients receive pembrolizumab as in Arm A. Patients also undergo SBRT once daily (QD) every other day for 3 fractions over 2 weeks that must be completed before 12 weeks after the first dose of pembrolizumab in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, bone scan, and/or PET scan, as well as optional urine and blood sample collection throughout the study.
After completion of study treatment, patients are followed up within 12 weeks and then every 3 months for 3 years following registration.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Littleton, Colorado, United States, 80122
- Suspended
- Littleton Adventist Hospital
-
-
Illinois
-
Bloomington, Illinois, United States, 61704
- Recruiting
- Illinois CancerCare-Bloomington
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Canton, Illinois, United States, 61520
- Recruiting
- Illinois CancerCare-Canton
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Carthage, Illinois, United States, 62321
- Recruiting
- Illinois CancerCare-Carthage
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Centralia, Illinois, United States, 62801
- Recruiting
- Centralia Oncology Clinic
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois
-
Contact:
- Site Public Contact
- Phone Number: 312-355-3046
-
Principal Investigator:
- Natalie Reizine
-
Chicago, Illinois, United States, 60612
- Active, not recruiting
- Rush University Medical Center
-
Danville, Illinois, United States, 61832
- Recruiting
- Carle at The Riverfront
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Vamsi K. Vasireddy
-
Decatur, Illinois, United States, 62526
- Recruiting
- Cancer Care Specialists of Illinois - Decatur
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, United States, 62526
- Recruiting
- Decatur Memorial Hospital
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, United States, 62401
- Recruiting
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Vamsi K. Vasireddy
-
Effingham, Illinois, United States, 62401
- Recruiting
- Crossroads Cancer Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Eureka, Illinois, United States, 61530
- Recruiting
- Illinois CancerCare-Eureka
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Galesburg, Illinois, United States, 61401
- Recruiting
- Illinois CancerCare-Galesburg
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Kewanee, Illinois, United States, 61443
- Recruiting
- Illinois CancerCare-Kewanee Clinic
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Macomb, Illinois, United States, 61455
- Recruiting
- Illinois CancerCare-Macomb
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Mattoon, Illinois, United States, 61938
- Recruiting
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Vamsi K. Vasireddy
-
O'Fallon, Illinois, United States, 62269
- Suspended
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, United States, 61350
- Recruiting
- Illinois CancerCare-Ottawa Clinic
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Pekin, Illinois, United States, 61554
- Recruiting
- Illinois CancerCare-Pekin
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peoria, Illinois, United States, 61615
- Recruiting
- Illinois CancerCare-Peoria
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peoria, Illinois, United States, 61637
- Recruiting
- OSF Saint Francis Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peru, Illinois, United States, 61354
- Recruiting
- Illinois CancerCare-Peru
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Princeton, Illinois, United States, 61356
- Recruiting
- Illinois CancerCare-Princeton
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Springfield, Illinois, United States, 62702
- Recruiting
- Southern Illinois University School of Medicine
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-545-7929
-
Springfield, Illinois, United States, 62702
- Recruiting
- Springfield Clinic
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 800-444-7541
-
Springfield, Illinois, United States, 62781
- Recruiting
- Memorial Medical Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-528-7541
- Email: pallante.beth@mhsil.com
-
Urbana, Illinois, United States, 61801
- Recruiting
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Vamsi K. Vasireddy
-
Washington, Illinois, United States, 61571
- Recruiting
- Illinois CancerCare - Washington
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
-
Iowa
-
Ankeny, Iowa, United States, 50023
- Recruiting
- Mission Cancer and Blood - Ankeny
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-282-2921
-
Clive, Iowa, United States, 50325
- Recruiting
- Mercy Cancer Center-West Lakes
-
Principal Investigator:
- Richard L. Deming
-
Contact:
- Site Public Contact
- Phone Number: 515-358-6613
- Email: cancerresearch@mercydesmoines.org
-
Creston, Iowa, United States, 50801
- Recruiting
- Greater Regional Medical Center
-
Principal Investigator:
- Richard L. Deming
-
Contact:
- Site Public Contact
- Phone Number: 515-358-6613
- Email: cancerresearch@mercydesmoines.org
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Medical Oncology and Hematology Associates-Des Moines
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Des Moines, Iowa, United States, 50314
- Recruiting
- Broadlawns Medical Center
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-282-2200
-
Des Moines, Iowa, United States, 50314
- Recruiting
- Mercy Medical Center - Des Moines
-
Principal Investigator:
- Richard L. Deming
-
Contact:
- Site Public Contact
- Phone Number: 515-358-6613
- Email: cancerresearch@mercydesmoines.org
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Iowa Methodist Medical Center
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-241-6727
-
West Des Moines, Iowa, United States, 50266
- Recruiting
- Mercy Medical Center-West Lakes
-
Principal Investigator:
- Richard L. Deming
-
Contact:
- Site Public Contact
- Phone Number: 515-358-6613
- Email: cancerresearch@mercydesmoines.org
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Recruiting
- Saint Joseph Mercy Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Brighton, Michigan, United States, 48114
- Recruiting
- Saint Joseph Mercy Brighton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Brighton, Michigan, United States, 48114
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Canton, Michigan, United States, 48188
- Recruiting
- Saint Joseph Mercy Canton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Canton, Michigan, United States, 48188
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Chelsea, Michigan, United States, 48118
- Recruiting
- Saint Joseph Mercy Chelsea
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Chelsea, Michigan, United States, 48118
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Lansing, Michigan, United States, 48912
- Recruiting
- University of Michigan Health - Sparrow Lansing
-
Principal Investigator:
- Elie G. Dib
-
Contact:
- Site Public Contact
- Phone Number: 517-364-3712
- Email: harsha.trivedi@umhsparrow.org
-
Livonia, Michigan, United States, 48154
- Recruiting
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
Ypsilanti, Michigan, United States, 48197
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Elie G. Dib
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- Recruiting
- Saint Luke's Hospital of Duluth
-
Principal Investigator:
- Steven R. Bonin
-
Contact:
- Site Public Contact
- Phone Number: 218-249-7825
- Email: kdean@slhduluth.com
-
-
Missouri
-
Cape Girardeau, Missouri, United States, 63703
- Recruiting
- Saint Francis Medical Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 573-334-2230
- Email: sfmc@sfmc.net
-
Columbia, Missouri, United States, 65212
- Active, not recruiting
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Farmington, Missouri, United States, 63640
- Recruiting
- Parkland Health Center - Farmington
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 314-996-5569
-
Saint Louis, Missouri, United States, 63141
- Recruiting
- Mercy Hospital Saint Louis
-
Principal Investigator:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Phone Number: 314-251-7066
-
Saint Louis, Missouri, United States, 63131
- Recruiting
- Missouri Baptist Medical Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 314-996-5569
-
Sainte Genevieve, Missouri, United States, 63670
- Recruiting
- Sainte Genevieve County Memorial Hospital
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 314-996-5569
-
Sullivan, Missouri, United States, 63080
- Recruiting
- Missouri Baptist Sullivan Hospital
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 314-996-5569
-
Sunset Hills, Missouri, United States, 63127
- Recruiting
- BJC Outpatient Center at Sunset Hills
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 314-996-5569
-
-
Montana
-
Bozeman, Montana, United States, 59715
- Recruiting
- Bozeman Deaconess Hospital
-
Principal Investigator:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Phone Number: 406-969-6060
- Email: mccinfo@mtcancer.org
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- NYP/Weill Cornell Medical Center
-
Principal Investigator:
- Himanshu Nagar
-
Contact:
- Site Public Contact
- Phone Number: 212-746-1848
-
-
Oklahoma
-
Lawton, Oklahoma, United States, 73505
- Recruiting
- Cancer Centers of Southwest Oklahoma Research
-
Contact:
- Site Public Contact
- Phone Number: 877-231-4440
-
Principal Investigator:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Phone Number: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Principal Investigator:
- Adanma Anji Ayanambakkam Attanathi
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Recruiting
- Geisinger Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 570-271-5251
- Email: HemonCCTrials@geisinger.edu
-
Principal Investigator:
- Fiori Alite
-
Lewisburg, Pennsylvania, United States, 17837
- Recruiting
- Geisinger Medical Oncology-Lewisburg
-
Contact:
- Site Public Contact
- Phone Number: 570-374-8555
- Email: HemonCCTrials@geisinger.edu
-
Principal Investigator:
- Fiori Alite
-
Philadelphia, Pennsylvania, United States, 19107
- Active, not recruiting
- Thomas Jefferson University Hospital
-
Pottsville, Pennsylvania, United States, 17901
- Recruiting
- Geisinger Cancer Services-Pottsville
-
Contact:
- Site Public Contact
- Phone Number: 800-275-6401
- Email: HemonCCTrials@geisinger.edu
-
Principal Investigator:
- Fiori Alite
-
Wilkes-Barre, Pennsylvania, United States, 18711
- Recruiting
- Geisinger Wyoming Valley/Henry Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 570-271-5251
- Email: HemonCCTrials@geisinger.edu
-
Principal Investigator:
- Fiori Alite
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Principal Investigator:
- Suzanne M. Cole
-
Dallas, Texas, United States, 75237
- Recruiting
- UT Southwestern Simmons Cancer Center - RedBird
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Principal Investigator:
- Suzanne M. Cole
-
Fort Worth, Texas, United States, 76104
- Recruiting
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Principal Investigator:
- Suzanne M. Cole
-
Richardson, Texas, United States, 75080
- Recruiting
- UT Southwestern Clinical Center at Richardson/Plano
-
Contact:
- Site Public Contact
- Phone Number: 972-669-7044
- Email: Suzanne.cole@utsouthwestern.edu
-
Principal Investigator:
- Suzanne M. Cole
-
-
Virginia
-
Mechanicsville, Virginia, United States, 23116
- Recruiting
- VCU Massey Cancer Center at Hanover Medical Park
-
Contact:
- Site Public Contact
- Email: CTOclinops@vcu.edu
-
Principal Investigator:
- Asit K. Paul
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University/Massey Cancer Center
-
Contact:
- Site Public Contact
- Email: CTOclinops@vcu.edu
-
Principal Investigator:
- Asit K. Paul
-
Richmond, Virginia, United States, 23235
- Recruiting
- VCU Massey Cancer Center at Stony Point
-
Contact:
- Site Public Contact
- Email: CTOclinops@vcu.edu
-
Principal Investigator:
- Asit K. Paul
-
-
Wisconsin
-
Eau Claire, Wisconsin, United States, 54701
- Recruiting
- Marshfield Medical Center-EC Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Marshfield, Wisconsin, United States, 54449
- Recruiting
- Marshfield Medical Center-Marshfield
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
Contact:
- Site Public Contact
- Phone Number: 414-805-3666
-
Principal Investigator:
- Ariel Nelson
-
Minocqua, Wisconsin, United States, 54548
- Recruiting
- Marshfield Clinic-Minocqua Center
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Mukwonago, Wisconsin, United States, 53149
- Recruiting
- ProHealth D N Greenwald Center
-
Contact:
- Site Public Contact
- Email: research.institute@phci.org
-
Principal Investigator:
- Timothy R. Wassenaar
-
Oconomowoc, Wisconsin, United States, 53066
- Recruiting
- ProHealth Oconomowoc Memorial Hospital
-
Principal Investigator:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Phone Number: 262-928-7878
-
Rice Lake, Wisconsin, United States, 54868
- Recruiting
- Marshfield Medical Center-Rice Lake
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Stevens Point, Wisconsin, United States, 54482
- Recruiting
- Marshfield Medical Center-River Region at Stevens Point
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Waukesha, Wisconsin, United States, 53188
- Recruiting
- UW Cancer Center at ProHealth Care
-
Principal Investigator:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Phone Number: 262-928-5539
- Email: Chanda.miller@phci.org
-
Weston, Wisconsin, United States, 54476
- Recruiting
- Marshfield Medical Center - Weston
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed metastatic urothelial carcinoma
Patients must be either ineligible for platinum treatment or platinum refractory as defined below:
Platinum-ineligible: If patients meet any one of the following criteria:
- Impaired renal function (creatinine clearance [CrCl] of < 30 mL/min)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of > 2
- Grade > 2 peripheral neuropathy
- New York Heart Association (NYHA) Heart Failure of > 3
Platinum-refractory: If patients meet any one of the following criteria:
- Prior platinum-based perioperative chemotherapy within 12 months of relapse
- Prior platinum-based chemotherapy for metastatic disease
- Patients must have at least one measurable site >= 1 cm in diameter per RECIST 1.1 and a site targetable for radiotherapy. Measurable site must not overlap with radiated site such that measurable site cannot receive > 2 Gy per fraction
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions)
- Men and women, ages >= 18 years of age
- ECOG performance status =< 2
- Leukocytes >= 2,500/mm^3
- Absolute neutrophil count >= 1,500/mm^3
- Platelets >= 100,000/mm^3
- Hemoglobin >= 8 g/dL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x upper limit of normal (ULN)
- AST and/or ALT =< 5 x ULN for patients with liver involvement
Alkaline phosphatase =< 2.5 x ULN
- =< 5 x ULN for patients with documented liver involvement or if due to bone metastases primarily in absence of liver disease, no limitation
- No prior allogeneic bone marrow transplantation or prior solid organ transplantation
- No prior radiotherapy to targetable site or measurable site
No chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier. However, the following therapies are allowed:
- Hormone-replacement therapy or oral contraceptives
- Palliative radiotherapy for bone metastases > 2 weeks prior to registration
- No prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- No treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
- No prior treatment with any other investigational agent within 4 weeks prior to registration
- No prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to registration
- Any prior systemic therapy is permitted except therapy with PD1/PDL1 inhibitor
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
- No active tuberculosis (TB)
- No known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions:
Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:
- Evaluable or measurable disease outside the CNS
- No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)
- No history of intracranial hemorrhage or spinal cord hemorrhage
- No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted
- No neurosurgical resection or brain biopsy within 28 days prior to registration
Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:
- Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study
- No stereotactic radiation or whole-brain radiation within 28 days prior to registration
- Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids
- No active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible
- No known history of, or any evidence of active, non-infectious pneumonitis or colitis
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- No known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; or inherited liver disease causing decompensated cirrhosis
- No history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- No significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
- No other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
- No history of leptomeningeal disease
- No uncontrolled tumor-related pain
- Patients requiring pain medication must be on a stable regimen at study entry
- Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period
- Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
No uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- Patients with indwelling catheters (e.g., PleurX [registered trademark]) are allowed
- Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
- No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- No active infections requiring systemic antibiotics within 2 weeks prior to registration. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
- No major surgical procedure within 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study
- No administration of a live, attenuated vaccine within 30 days before registration or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of immunotherapy
- Patients who have received live attenuated vaccines within 30 days of the first dose of trial treatment are eligible at the discretion of the investigator. All seasonal influenza vaccines and vaccines intended to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) are allowed
Physicians should consider whether any of the following may render the patient inappropriate for this protocol:
- Patients with life expectancy of less than 6 months
- Psychiatric illness which would prevent the patient from giving informed consent
Medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for >= 3 years
Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study and for 4 months (120 days) after the last dose of study agent due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (pembrolizumab)
Patients receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle.
Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo CT scan, MRI, bone scan and/or PET scan, as well as optional urine and blood sample collection throughout the study.
|
Ancillary studies
Undergo MRI
Other Names:
Given IV
Other Names:
Undergo PET scan
Other Names:
Undergo CT scan
Other Names:
Undergo bone scan
Other Names:
Undergo urine and blood sample collection
Other Names:
|
Experimental: Arm B (pembrolizumab, SBRT)
Patients receive pembrolizumab as in Arm A. Patients also undergo SBRT QD every other day for 3 fractions over 2 weeks that must be completed before 12 weeks after the first dose of pembrolizumab in the absence of disease progression or unacceptable toxicity.
Patients undergo CT scan, MRI, bone scan, and/or PET scan, as well as optional urine and blood sample collection throughout the study.
|
Ancillary studies
Undergo MRI
Other Names:
Given IV
Other Names:
Undergo SBRT
Other Names:
Undergo PET scan
Other Names:
Undergo CT scan
Other Names:
Undergo bone scan
Other Names:
Undergo urine and blood sample collection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: Up to 6 months from randomization
|
Will be defined as a complete response (CR) or partial response (PR) as assessed by the treating physician using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
|
Up to 6 months from randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 3 years from randomization
|
Will be assessed by Common Terminology Criteria for Adverse Events version 5.0.
Adverse events will be summarized with frequencies and relative frequencies.
|
Up to 3 years from randomization
|
Tumor response
Time Frame: Up to 3 years from randomization
|
Will be determined to have a tumor response if they have a CR or PR as assessed by immune modified RECIST.
|
Up to 3 years from randomization
|
Progression-free survival
Time Frame: Time from randomization until disease progression as assessed by the treating physician using RECIST 1.1 or death due to any cause, assessed up to 3 years
|
Stratified Cox models will be used to compare the outcomes between the two treatment groups.
The results will be summarized with a forest plot displaying the estimate of the hazard ratio and corresponding 95% confidence interval.
|
Time from randomization until disease progression as assessed by the treating physician using RECIST 1.1 or death due to any cause, assessed up to 3 years
|
Overall survival
Time Frame: Time from randomization until death due to any cause. Patients who are not known to be dead at time of analysis will be censored at the time of their last follow-up, assessed up to 3 years
|
Stratified Cox models will be used to compare the outcomes between the two treatment groups.
The results will be summarized with a forest plot displaying the estimate of the hazard ratio and corresponding 95% confidence interval.
|
Time from randomization until death due to any cause. Patients who are not known to be dead at time of analysis will be censored at the time of their last follow-up, assessed up to 3 years
|
Rate of treatment discontinuation
Time Frame: At 1 year
|
The proportion of patients who discontinue their protocol directed treatment prior to one year from date of study registration will be determined.
Patients who stop their protocol directed treatment for any reason prior to one year from study registration will be considered to have discontinued their treatment.
The rates of treatment discontinuation at one year will be summarized with a binomial point estimate and corresponding 95% confidence interval by arm.
A comparison between the rates will be performed with a chi-square test or a Fisher's exact test if the assumptions of the chi-square test are violated.
|
At 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Himanshu Nagar, Alliance for Clinical Trials in Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2021-06326 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180821 (U.S. NIH Grant/Contract)
- A032002 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditionsUnited States, Puerto Rico
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditionsUnited States
-
Shanghai Miracogen Inc.RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial CancerChina
-
Incyte CorporationTerminatedMetastatic Urothelial Carcinoma | Unresectable Urothelial CarcinomaSpain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation